Clinion GBL/GEMCOVAC-19 ePRO
This is Prospective, Multi-centre, Open-labelled, Randomized, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of GEMCOVAC-OM as a booster in Subjects 18 years of age and older. Thus, completion of subject diary is very important as this